BOEHRINGER-INGELHEIM
29.10.2021 09:02:12 CEST | Business Wire | Press release
Boehringer Ingelheim announced today that the company’s marketing authorization application (MAA) for the treatment of flares in generalized pustular psoriasis (GPP), has been validated and is now under evaluation with the European Medicines Agency (EMA).
“GPP is a rare, life-threatening neutrophilic skin disease characterized by painful, sterile pus-filled blisters, that can suddenly appear over the body,” said Dr. Janine Lamar, Global Spesolimab Lead at Boehringer Ingelheim. “Despite its name, GPP is very different to the more common plaque psoriasis. With no approved treatments in the EU for GPP flares, acceptance of the application for review of spesolimab brings us one step closer to providing a targeted treatment for people with this distressing, unpredictable and painful skin condition.”
GPP is characterized by episodes of widespread eruptions of painful, sterile pustules (blisters of non-infectious pus).1,2,3 The inflammation can also affect other parts of the body and can lead to infections or other organ complications that may be life-threatening.
There is a high unmet need for treatments that can rapidly and completely resolve the symptoms of GPP flares. Flares greatly affect a person’s quality of life4 and can lead to hospitalization with life-threatening complications, such as heart failure, renal failure, sepsis and even death.5
The marketing authorization application was based on the 12 week Effisayil-1 trial; a multi-center, double-blind, randomized, placebo-controlled trial that evaluated efficacy, safety, and tolerability of spesolimab (single dose 900 mg spesolimab i.v., with the option of a 2nd dose if symptoms persisted on Day 8) in patients experiencing a GPP flare.6 The study demonstrated superiority over placebo in pustular clearance after one week of treatment.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/ema-filing-acceptance-and-validation-spesolimab
View source version on businesswire.com: https://www.businesswire.com/news/home/20211029005027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The LYCRA Company Launches LYCRA® ADAPTIV fiber for Nonwovens, Advancing Comfort and Fit in Disposable Hygiene at INDEX™ 2613.5.2026 14:00:00 CEST | Press release
Innovation Nominated for INDEX™ 26 Award for Delivering Consistent Fit Across Expanded Size Ranges The LYCRA Company, a leader in innovative and sustainable fibers for apparel and personal care, today announced the official global launch of LYCRA® ADAPTIV fiber for nonwovens at INDEX™ 26, in Geneva, Switzerland, May 19–22. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514856391/en/ At INDEX™ 26 in Geneva, The LYCRA Company debuts LYCRA® ADAPTIV fiber for nonwovens, a next-generation stretch solution that delivers enhanced comfort, a secure fit, and helps enable inclusive sizing for baby diapers, adult incontinence, and feminine care products. This breakthrough stretch fiber, already trusted by leading global apparel brands, now ushers in a new era of comfort, fit, and performance for baby diapers, disposable hygiene products, adult incontinence, and feminine care. LYCRA® ADAPTIV fiber is engineered to address key unmet n
Adtran expands SDG 8700 Series to deliver Wi-Fi 7 at scale13.5.2026 14:00:00 CEST | Press release
News summary: Service providers are replacing aging in-home Wi-Fi equipment as expectations rise and competitive pressure accelerates next-generation Wi-Fi adoption SDG 8700 Series now supports Wi-Fi 7 across the full range of mass-market residential to premium SMB service offerings Expanded portfolio delivers scalable, high-quality Wi-Fi 7 experiences while maintaining operational consistency and regulatory readiness Adtran today announced an expansion of its SDG 8700 Series, extending Wi-Fi 7 across a broader range of residential service tiers and deployment models. The expanded portfolio introduces new 2.5Gbit/s and 10Gbit/s Wi-Fi 7 platforms designed to support the full spectrum of multigigabit services – from entry-level offerings to premium tiers – across residential, SMB, MDU and community Wi-Fi deployments. As service providers enter a new access refresh cycle, Wi-Fi 7 is rapidly becoming a baseline requirement rather than a premium differentiator. Adtran’s expanded SDG 8700 po
Austrian Broadband Operator Deploys Vecima’s Entra® vCMTS and Remote PHY Devices to Advance its Next-Generation DOCSIS® Network13.5.2026 13:45:00 CEST | Press release
Operator selects cloud-native vCMTS and Remote PHY architecture for a flexible, phased migration to Distributed Access Architecture (DAA) Vecima Networks Inc. (TSX: VCM) and Witke today announced that an Austrian broadband operator is deploying the Entra® virtualized Cable Modem Termination System (vCMTS) as the DOCSIS® platform for its Distributed Access Architecture (DAA) evolution. The deployment, led by Witke, enables advanced reliability, scalable capacity expansion over time, and a clear migration path toward DOCSIS 4.0 broadband services. After extensive system planning and evaluation, the operator selected a vCMTS and Remote PHY (R-PHY) architecture to align with its long-term network roll-out strategy and migration requirements. The deployment provides the flexibility to modernize the network in phases while reducing space, power, and cooling requirements across the operator’s infrastructure. Entra vCMTS establishes a new standard for simplified, virtualized Cable Access, comb
Vecima, Incognito, and BM COM Announce Turnkey Fiber Broadband Solutions at ANGA COM 202613.5.2026 13:30:00 CEST | Press release
Strategic collaboration delivers fully integrated, turnkey fiber broadband solutions that are interoperable and multi-vendor, with no single vendor lock-inJoint “Broadband-in-a-Box” solution combines infrastructure, software, and system integration to accelerate fiber deployments worldwide Vecima Networks Inc., Incognito Software Systems Inc., and BM COM s.r.o., today announced a strategic collaboration to deliver a fully integrated, turnkey fiber broadband solution, which will be showcased at ANGA COM 2026, May 19–21 in Cologne, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513492655/en/ The joint solution brings together best-in-class fiber access infrastructure, advanced service orchestration, and in-market deployment expertise into a unified, interoperable Broadband-in-a-Box platform without requiring single vendor lock-in. Designed to simplify and accelerate fiber broadband rollouts, the solution enables op
Veristat Launches AI Biostatistics Platform, Cutting Clinical Trial Data Readout Time from 5 Weeks to 5 Days* Without Regulatory Risks13.5.2026 13:05:00 CEST | Press release
InStat™ delivers submission-ready tables, lists and figures (TLF) on validated statistical engines, with Clene Nanomedicine as its first customer Veristat™, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced the launch of InStat™ by Veristat. InStat is the clinical research industry’s first zero-code, fully automated biostatistics solution, reducing manual effort to speed time to approval with every output backed by validated statistical engines and expert biostatistician review. It delivers submission-ready tables, listings, and figures (TLF) in five days or less*, rather than the four to six weeks sponsors typically wait after database lock, while maintaining the highest quality data. Veristat will begin using InStat to deliver biostatistics services in June. Clene Nanomedicine is the first clinical trial sponsor whose work was delivered using InStat, with NfL biomarker analyses supporting their planned 2026 New Drug Application (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom